Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.41 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.39 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL244566 | 0.86 | KCNH2 (0.39) | KCNH2CYP2C8ANO1 | |
| SCHEMBL253936 | 0.84 | KCNH2 (0.47) | KCNH2CYP2C8HIPK4DDR2 | |
| SCHEMBL9947767 | 0.82 | KCNH2 (0.41) | KCNH2CYP2C8HIPK4DDR2ANO1 | |
| SCHEMBL2843961 | 0.80 | ANO1 (0.51) | KCNH2CYP2C8ANO1CYP3A4 | |
| SCHEMBL14217295 | 0.79 | KCNH2 (0.43) | KCNH2CYP2C8CYP3A4 | |
| SCHEMBL16112945 | 0.78 | KCNH2 (0.41) | KCNH2CYP2C8CYP3A4 | |
| SCHEMBL246247 | 0.77 | DDR2 (0.39) | KCNH2CYP2C8HIPK4DDR2ANO1 | |
| SCHEMBL1918982 | 0.77 | KCNH2 (0.52) | KCNH2CYP2C8 | |
| SCHEMBL1918302 | 0.76 | KCNH2 (0.44) | KCNH2CYP2C8ANO1CYP3A4 | |
| SCHEMBL18038578 | 0.75 | CYP3A4 (0.42) | KCNH2CYP2C8CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588464-B1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITS C | BRISTOL MYERS SQUIBB CO (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8445497-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2588464-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITS C | Bristol-Myers Squibb Company (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20120165344-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-28 | — | — | US | disclosed |
| WO-2012003164-A1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165344-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | KCNH2 3814/4885CYP2C8 85/4885HIPK4 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.